



RECEIVED
JAN 8 1 2003
TECH CENTER 1800/2800

1645
A#9

PATENT
Attorney Docket No. A-70219-1/RMS/DHR
Dorsey File No. 467802-52

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MANCEBO et al.

Serial No.: 10/043,649

Filing Date: January 10, 2002

For: Cloning of a Novel Inhibitor of
Antigen-Receptor Signaling by a
Retroviral-Based Functional Screen

Examiner: UNKNOWN

Art Unit: 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on:

Dated: January 27, 2003

Signed: Marjorie Jost
Marjorie Jost

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the reference cited on the accompanying substitute for form PTO-1449. Copies of the cited references are enclosed herewith.

None of the foregoing references is believed to disclose the invention as claimed. Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Serial No.: 10/043,649
Filing Date: January 10, 2002

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no fee is currently believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 467802-52 (A-70219-1/RMS/DHR)).

Please direct any calls in connection with this application to the undersigned at
(415) 781-1989.

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: 1/27/03
Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

BY: Robin M. Silva
Robin M. Silva, Reg. No. 38,304
Filed under 37 C.F.R. § 1.34(a)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/043,649		
		Filing Date	January 10, 2002		
		First Named Inventor	MANCEBO, Helen		
		Group Art Unit	1645		
		Examiner Name			
Sheet	1	of	2	Attorney Docket Number	A-70219-1/RMS/DHR (467802-52)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				
	A2				
	A3				
	A4				
	A5				
	A6				

RECEIVED
JAN 31 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ² Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO 95/26983 A2	10-12-1995	MAX-PLANCK-GESELLSCHAFT	PP 7-8, 15, claims 1-4	
	B2	WO 00/58473 A2	10-05-2000	CURAGEN CORPORATION	pp 4690-4692	
	B3	WO 02/16599 A2	02-28-2002	CURAGEN CORPORATION	pp 97-104, claims 1-49	
	B4	WO 02/42452 A2	05-30-2002	HOSPITAL FOR SICK CHILDREN	claims 1-39, ex. 1-2, table 4	
	B5	WO 02/42457 A1	05-30-2002	BRISTOL-MYERS SQUIBB	claims 1-20, fig. 1-2, ex. 1-7	


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
	C1	PANDEY A et al., "Characterization of a Novel Src-Like Adapter Protein that Associates with the Eck Receptor Tyrosine Kinase," <i>J. Biol. Chem.</i> 270(33):19201-19204 (Aug. 1995)				
	C2	Database EMBL Online, Acc. No. Q60898, Nov. 1, 1996. Src-like adapter protein				
	C3	TANG, J et al., "SLAP, a dimeric adapter protein, plays a functional role in T cell receptor signaling," <i>Proc. Nat. Acad. Sci. USA</i> 96:9775-9780 (1999)				
	C4	Database EMBL Online, Acc. No. AK025645, Sep. 29, 2000. Homo sapiens cDNA: FLJ21992 fis, clone HEP06554				
	C5	Database EMBL Online, Acc. No. AL050318, May 26, 1999. Human DNA sequence from clone RP5-977B1 on chromosome 20 Contains ESTs, STSs, GSSs and three putative CpG islands.				
	C6	Database EMBL Online, Acc. No. AI430952, Mar. 16, 1999. mj43c04.x1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:478854 3' similar to TR:Q13239 Q13239 PUTATIVE SRC-LIKE ADAPTER PROTEIN; mRNA sequence.				
	C7	Database EMBL Online, Acc. No. AA959151, May 11, 1998. vz51g06.r1 Soares 2NbMT Mus musculus cDNA clone IMAGE:1330042 5' similar to TR:Q13239 Q13239 PUTATIVE SRC-LIKE ADAPTER PROTEIN, mRNA sequence.				
	C8	Database EMBL Online, Acc. No. AI510095, Mar. 17, 1999. mj43c04.y1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:478854 5' similar to TR:Q13239 Q13239 PUTATIVE SRC-LIKE ADAPTER PROTEIN; mRNA sequence.				

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1101652_1.DOC



Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/043,649		
		Filing Date	January 10, 2002		
		First Named Inventor	MANCEBO, Helen		
		Group Art Unit	1645		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	A-70219-1/RMS/DHR (467802-52)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
	C9	Holland SJ, et al., "Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling." <i>J Exp Med.</i> 2001 Nov 5;194(9):1263-76.	
	C10	Sosinowski T, et al., "Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling." <i>J Exp Med.</i> 2000 Feb 7;191(3):463-74.	
	C11	Database EMBL Online, Acc. No. AF290985. Dec. 9, 2001. Homo sapiens Src-like adaptor protein-2 mRNA, complete cds.	
	C12	Database Genbank online, Acc. No. AF326353. Nov. 8, 2001. Homo Sapiens Src-like adapter protein-2 mRNA, complete cds.	
	C13	Database Genbank online, Acc. No. NM_006748. Nov. 5, 2002. Homo sapiens Src-like-adaptor (SLA), mRNA.	
	C14	Rudd CE, and Schneider H. "Lymphocyte signaling: Cbl sets the threshold for autoimmunity." <i>Curr Biol.</i> 2000 May 4;10(9):R344-7.	
	C15	Ota S, et al., "The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase." <i>J Biol Chem.</i> 2000 Jan 7;275(1):414-22.	
	C16	Rao N, et al., "The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells." <i>J Immunol.</i> 2000 May 1;164(9):4616-26.	

RECEIVED
JAN 31 2003
TECH CENTER 1800/2800

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1101652_1.DOC